Antigua and Barbuda vs Iraq: Average non-HDL cholesterol levels
Antigua and Barbuda
3.5
in 2018
Iraq
3.5
in 2018
Antigua and Barbuda rank
52nd
Iraq rank
52nd
Average non-HDL cholesterol levels over time
- Antigua and Barbuda
- Iraq
How they compare
Antigua and Barbuda currently reports 3.5 against 3.5 in Iraq, a difference of 0.
Across all 39 years both countries report, Iraq has been ahead every year.
Antigua and Barbuda ranks 52nd and Iraq ranks 52nd of 191 countries.
Iraq has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Antigua and Barbuda | Iraq | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.23 | 3.75 | 0.52 | Iraq |
| 1990s | 3.3 | 3.8 | 0.5 | Iraq |
| 2000s | 3.31 | 3.75 | 0.44 | Iraq |
| 2010s | 3.43 | 3.58 | 0.1444 | Iraq |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average non-hdl cholesterol levels, Antigua and Barbuda or Iraq?
- Antigua and Barbuda, at 3.5 against 3.5 in Iraq as of 2018.
- What is the difference in average non-hdl cholesterol levels between Antigua and Barbuda and Iraq?
- 0, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and Iraq?
- 39 years are reported by both, from 1980 to 2018.
- How do Antigua and Barbuda and Iraq rank globally for average non-hdl cholesterol levels?
- Antigua and Barbuda ranks 52nd and Iraq ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The estimated average level of non-high-density lipoprotein (non-HDL) cholesterol, commonly known as "bad cholesterol". Healthy levels are considered to be under 4mmol/L. Elevated levels of non-HDL cholesterol are a risk factor for chronic complications, including cardiovascular disease, and premature death.